UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
The Development of Selective Inhibitors to Oncogenic Rac1 Variants
The Development of Selective Inhibitors to Oncogenic Rac1 Variants is a funding opportunity from UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, up to 42277, closing August 31, 2028.
Aug 31, 2028
(762d left)Overview
PROJECT SUMMARY Rac1, a member of the Rho GTPase subfamily, regulates essential cellular functions including cytoskeletal arrangement, cell motility, cell cycle progression, and proliferation. Dysregulation of Rac1, such as through the oncogenic P29S mutation or the expression of the alternative splice variant Rac1b,…